#France #Guerbet #Villepinte #Lipiodol #Vascular Embolization

Guerbet Achieves Regulatory Milestone for Lipiodol® Ultra Fluid in Vascular Embolization

Guerbet, a prominent name in medical imaging, has recently celebrated a pivotal achievement concerning its product Lipiodol® Ultra Fluid. This iodinated ethyl ester derived from poppy seed oil has gained a new indication for use in vascular embolization procedures within interventional radiology. This milestone is particularly noteworthy following a collaborative worksharing procedure that included multiple EU member states.

The newly granted indication allows Lipiodol to be utilized alongside cyanoacrylate-based surgical glues, approved for endovascular use. These enhancements provide clinicians with vital tools for visualizing the embolization process and adjusting the polymerization time accordingly.

François Convenant, Senior Vice President of Interventional Radiology at Guerbet, underscored this accomplishment, stating, "This regulatory achievement for Lipiodol’s indication in vascular embolization marks a significant milestone for our field. Its radiopacity and physicochemical properties enable more controlled, predictable, and safe embolization procedures. This indication formalizes years of clinical practice and paves the way for harmonizing glue embolization techniques across Europe."

Scientific Rationale and Clinical Impact

Interventional radiology has seen a rising demand for embolic agents that are characterized by precision, rapidity, and durability. Lipiodol, when paired with cyanoacrylate-based glues, becomes a controllable and radiopaque liquid embolic agent. This advancement holds the promise of:

• - Real-Time Visualization: Clinicians can observe the injection process, confirming vessel occlusion immediately.
• - Adjustable Viscosity and Polymerization Time: Medical professionals can tailor embolization treatments for both proximal and distal vascular lesions, improving procedural success and patient outcomes.
• - Enhanced Effectiveness: Lipiodol provides permanent occlusion, decreasing the likelihood of repeat procedures.

Guerbet’s Commitment to Healthcare Professionals

In light of this regulatory advance, Guerbet is reaffirming its dedication to interventional radiology teams across the European community. The company is enhancing its support through:

• - Comprehensive scientific and clinical assistance to healthcare professionals.
• - Tailored medical education programs aimed at skill enhancement and procedural knowledge.
• - Increased field presence, ensuring that clinical teams have access to timely and accurate information and resources.
• - Reliable solutions designed to maintain high standards of patient care while also being cost-effective for institutions.

About Guerbet

Founded with the mission to foster better living through medical advancements, Guerbet has established itself as a global leader in medical imaging. The organization boasts a diverse portfolio that includes pharmaceutical products, medical devices, and digital solutions for both diagnostic and interventional imaging. With over 2,746 employees worldwide, Guerbet invests heavily in innovation, allocating 10% of its revenue to research and development efforts across its centers in France and the United States.

Listed on Euronext Paris (ticker: GBT) and reporting a revenue of €786 million in 2025, Guerbet continues to pioneer advancements in the imaging sector. As the company moves forward, the implications of its latest milestone with Lipiodol® point toward a promising future for interventional radiology and patient care as a whole.

For more information about Guerbet and its initiatives, please visit www.guerbet.com.